Study: Merck’s cervical cancer vaccine is effective for five years
April 26 2006 11:00 PM ET
reported this week that ongoing studies of Merck’s
human papillomavirus vaccine Gardasil, which aims to
prevent cervical cancer caused by the virus, offers
long-lasting HPV protection for at least five years,
EuroToday reports. Study subjects receiving the experimental
vaccine were protected against cervical neoplasia and
external lesions, both precursors to cervical cancer,
through the five-year mark of the clinical trial.
Previous study data has shown the vaccine is 100%
effective in blocking infection with HPV strains 16 and 18,
which are responsible for about 70% of all cervical
cancer cases. The Food and Drug Administration is
currently reviewing an application to market Gardasil.
A decision is expected in early June. Cervical cancer is an
AIDS-defining condition for HIV-positive women.
- Brad Pitt and Angelina Jolie Support Their Kid Wearing Suits
- #TBT: They Died in the Closet
- Did Nickelodeon Just Confirm Legend of Korra Same-Sex Romance?
- Gay Comic Publisher Undaunted by Apple's iBook Censorship
- WATCH: Laverne Cox Caught in Middle of Screaming Match on The View
- This Year's Coolest Straight People in Entertainment